Scienture (NASDAQ:SCNX) Upgraded to “Hold” at Wall Street Zen

Wall Street Zen upgraded shares of Scienture (NASDAQ:SCNX) to a hold rating in a report published on Saturday morning.

A number of other brokerages have also issued reports on SCNX. Maxim Group initiated coverage on shares of Scienture in a research report on Tuesday, February 24th. They set a “buy” rating and a $1.50 target price on the stock. Weiss Ratings reissued a “sell (e+)” rating on shares of Scienture in a report on Monday, December 29th. One equities research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $1.50.

Scienture Stock Down 8.4%

Shares of SCNX stock opened at $0.47 on Friday. Scienture has a 12 month low of $0.37 and a 12 month high of $3.17. The firm has a market cap of $18.99 million, a PE ratio of -0.47 and a beta of 3.01. The stock has a 50 day moving average of $0.46 and a 200-day moving average of $0.65.

Institutional Trading of Scienture

An institutional investor recently raised its position in Scienture stock. Geode Capital Management LLC increased its position in shares of Scienture Holdings, Inc. (NASDAQ:SCNX) by 264.3% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 316,201 shares of the company’s stock after purchasing an additional 229,398 shares during the period. Geode Capital Management LLC owned about 0.78% of Scienture worth $161,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 5.68% of the company’s stock.

About Scienture

Scienture Holdings, Inc engages in the provision of health services and pharmaceutical products. It focuses on addressing underserved patients and indications through novel product concepts and innovation. The company was founded on July 15, 2005 and is headquartered in Lutz, FL.